Literature DB >> 21880609

Assessment of right ventricular functions during cancer chemotherapy.

Asli Tanindi1, Umut Demirci, Gulten Tacoy, Suleyman Buyukberber, Yakup Alsancak, Ugur Coskun, Ridvan Yalcin, Mustafa Benekli.   

Abstract

AIMS: Although systolic and diastolic left ventricular functions after cancer chemotherapy are well studied, there are a few investigations about the right ventricular functions. We aimed to investigate the early effects of chemotherapy on right heart, if any, in addition to the association between N-terminal pro-brain natriuretic peptide (NT-proBNP) and right heart echocardiographic indices. METHODS AND
RESULTS: Thirty-seven consecutive patients with newly diagnosed breast cancer who were planned to receive either AC protocol [cyclophosphamide (600 mg/m(2)) + adriamycin (60 mg/m(2))] or CAF protocol [cyclophosphamide (600 mg/m(2)) + adriamycin (60 mg/m(2)) + 5-fluorouracil (600 mg/m(2))] for six cures were enrolled between February 2009 and June 2010. Echocardiography was performed before the onset of the chemotheurapeutic regimen (T1), on the day after the completion of the first cure (T2), and after the completion of two cures of the regimen (T3). Serum NT-proBNP levels were also measured at T1, T2, and T3. The mean right ventricular fractional area change (RVFAC) was 63.7 ± 3.63, 63.3 ± 3.67, and 61.2 ± 4.41% at T1, T2, and T3, respectively (pT1-T3 and pT2-T3 <0.05). Tricuspid annular plane systolic excursion (TAPSE) has decreased in time (1.82 ± 0.2, 1.78 ± 0.19, and 1.62 ± 0.24 cm; pT1-T2, pT1-T3, and pT2-T3 were 0.002, <0.001, and <0.001, respectively). Tricuspid annular mean E'/A' ratios were 1.42 ± 0.16, 1.36 ± 0.18, and 1.11 ± 0.32 (pT1-T2 = 0.013, pT1-T3 < 0.001, and pT2-T3 < 0.001). Mean tricuspid annular systolic velocities were 11.35 ± 1.85, 11.0 ± 1.82, and 10.45 ± 1.75 cm/s for T1, T2, and T3; and the differences between T1 and T2, T1 and T3, and T2 and T3 were all significant (P = 0.005, <0.001, and 0.001). Median serum NT-proBNP levels were 82 (60-247), 116 (60-426), and 170 (60-600) pg/mL at T1, T2, and T3. The amount of change in RVFAC and TAPSE between T1 and T3 were found to be correlated with the amount of change in NT-proBNP measurements between T1 and T3 (R: -0.7, P < 0.001; R: -0.62, P < 0.001).
CONCLUSION: There is a subclinical decrease in right ventricular systolic and diastolic echocardiographic indices, although mostly, in the normal range, in a relatively short time interval after onset of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880609     DOI: 10.1093/ejechocard/jer142

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  26 in total

1.  Right ventricular function and mechanics in chemotherapy- and radiotherapy-naïve cancer patients.

Authors:  Marijana Tadic; Ana Baudisch; Sabine Haßfeld; Frank Heinzel; Cesare Cuspidi; Franziska Burkhardt; Felicitas Escher; Philipp Attanasio; Burkert Pieske; Martin Genger
Journal:  Int J Cardiovasc Imaging       Date:  2018-05-24       Impact factor: 2.357

2.  Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy.

Authors:  Fei-Yan Song; Jing Shi; Ye Guo; Chu-Jie Zhang; Yu-Chen Xu; Qun-Ling Zhang; Xian-Hong Shu; Lei-Lei Cheng
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-02       Impact factor: 2.357

Review 3.  The influence of chemotherapy on the right ventricle: did we forget something?

Authors:  Marijana Tadic; Cesare Cuspidi; Dagmara Hering; Lucia Venneri; Oleksandr Danylenko
Journal:  Clin Cardiol       Date:  2017-02-13       Impact factor: 2.882

4.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

Review 5.  Advanced heart failure due to cancer therapy.

Authors:  Sachin Shah; Anju Nohria
Journal:  Curr Cardiol Rep       Date:  2015       Impact factor: 2.931

Review 6.  Biomarkers in cancer therapy related cardiac dysfunction (CTRCD).

Authors:  Rohit Moudgil; Parag A Parekh
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

7.  Effects of folinic acid and fluorouracil chemotherapy on right ventricle func-tions as assessed with tricuspid annular plane systolic excursion.

Authors:  C Bilir; H Engin; T Karabag; D Colak
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

Review 8.  Personalized Approach to Cancer Treatment-Related Cardiomyopathy.

Authors:  Jeremy Slivnick; Ajay Vallakati; Daniel Addison; Alexander Wallner; Matthew S Tong
Journal:  Curr Heart Fail Rep       Date:  2020-04

9.  Speckle tracking echocardiography detects decreased cardiac longitudinal function in anthracycline-exposed survivors of childhood cancer.

Authors:  Kaisa Ylänen; Anneli Eerola; Kim Vettenranta; Tuija Poutanen
Journal:  Eur J Pediatr       Date:  2016-09-13       Impact factor: 3.183

Review 10.  Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.

Authors:  Wendy J Bottinor; Christopher K Migliore; Carrie A Lenneman; Marcus F Stoddard
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.